Bigul

Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Indoco successfully concludes USFDA inspection at Goa Plant II
16-10-2019
Bigul

Indoco Remedies Ltd - 532612 - Compliance Certificate For The Period Ended 30.09.2019

Regulation 7(3) of SEBI (LODR) Regulations, 2015
10-10-2019
Bigul

INDOCO REMEDIES LTD. - 532612 - Statement Of Investor Complaints For The Quarter Ended September 2019

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JAYSHANKAR MENONDesignation :- Company Secretary and Compliance Officer
10-10-2019
Bigul

Indoco Remedies Ltd - 532612 - Board Meeting Intimation for Unaudited Financial Results

INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2019 ,inter alia, to consider and approve Unaudited Financial Results for the quarter and half year ended 30.09.2019
10-10-2019
Bigul

Indoco Remedies Ltd - 532612 - Shareholding for the Period Ended September 30, 2019

Indoco Remedies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here
10-10-2019
Bigul

Indoco Remedies gets USFDA nod for Parkinson's disease treatment drug

New Delhi, October 7 Drug firm Indoco Remedies on Monday said it has received approval from the US health regulator for Rasagiline tablets, used for t
07-10-2019
Bigul

Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Indoco receives ANDA approval for Rasagiline tablets from USFDA
07-10-2019
Bigul

Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Indoco successfully completes UK-MHRA inspection at Goa II
23-09-2019
Next Page
Close

Let's Open Free Demat Account